Previous researches have demonstrated that inhibition of c-Met signaling, such as non-small cell lung cancer (NSCLC), HCC, GC, PC, CRC, ovarian cancer, bladder cancer (16–25), is an efficient anti-tumor strategy for many tumors. This evidence concerns the gene MET and non-small cell lung carcinoma.